These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
204 related articles for article (PubMed ID: 22496653)
1. Small-molecule inhibitors of dengue-virus entry. Schmidt AG; Lee K; Yang PL; Harrison SC PLoS Pathog; 2012; 8(4):e1002627. PubMed ID: 22496653 [TBL] [Abstract][Full Text] [Related]
2. Peptide inhibitors of dengue-virus entry target a late-stage fusion intermediate. Schmidt AG; Yang PL; Harrison SC PLoS Pathog; 2010 Apr; 6(4):e1000851. PubMed ID: 20386713 [TBL] [Abstract][Full Text] [Related]
3. Peptide inhibitors of flavivirus entry derived from the E protein stem. Schmidt AG; Yang PL; Harrison SC J Virol; 2010 Dec; 84(24):12549-54. PubMed ID: 20881042 [TBL] [Abstract][Full Text] [Related]
4. Peptide inhibitors of dengue virus and West Nile virus infectivity. Hrobowski YM; Garry RF; Michael SF Virol J; 2005 Jun; 2():49. PubMed ID: 15927084 [TBL] [Abstract][Full Text] [Related]
5. Discovery of Immunologically Inspired Small Molecules That Target the Viral Envelope Protein. Lian W; Jang J; Potisopon S; Li PC; Rahmeh A; Wang J; Kwiatkowski NP; Gray NS; Yang PL ACS Infect Dis; 2018 Sep; 4(9):1395-1406. PubMed ID: 30027735 [TBL] [Abstract][Full Text] [Related]
6. In silico screening of small molecule libraries using the dengue virus envelope E protein has identified compounds with antiviral activity against multiple flaviviruses. Kampmann T; Yennamalli R; Campbell P; Stoermer MJ; Fairlie DP; Kobe B; Young PR Antiviral Res; 2009 Dec; 84(3):234-41. PubMed ID: 19781577 [TBL] [Abstract][Full Text] [Related]
7. Molecular determinants of antiviral potency of paramyxovirus entry inhibitors. Porotto M; Carta P; Deng Y; Kellogg GE; Whitt M; Lu M; Mungall BA; Moscona A J Virol; 2007 Oct; 81(19):10567-74. PubMed ID: 17652384 [TBL] [Abstract][Full Text] [Related]
8. De novo design approaches targeting an envelope protein pocket to identify small molecules against dengue virus. Leal ES; Adler NS; Fernández GA; Gebhard LG; Battini L; Aucar MG; Videla M; Monge ME; Hernández de Los Ríos A; Acosta Dávila JA; Morell ML; Cordo SM; García CC; Gamarnik AV; Cavasotto CN; Bollini M Eur J Med Chem; 2019 Nov; 182():111628. PubMed ID: 31472473 [TBL] [Abstract][Full Text] [Related]
9. A small molecule fusion inhibitor of dengue virus. Poh MK; Yip A; Zhang S; Priestle JP; Ma NL; Smit JM; Wilschut J; Shi PY; Wenk MR; Schul W Antiviral Res; 2009 Dec; 84(3):260-6. PubMed ID: 19800368 [TBL] [Abstract][Full Text] [Related]
11. Inhibition of Flaviviruses by Targeting a Conserved Pocket on the Viral Envelope Protein. de Wispelaere M; Lian W; Potisopon S; Li PC; Jang J; Ficarro SB; Clark MJ; Zhu X; Kaplan JB; Pitts JD; Wales TE; Wang J; Engen JR; Marto JA; Gray NS; Yang PL Cell Chem Biol; 2018 Aug; 25(8):1006-1016.e8. PubMed ID: 29937406 [TBL] [Abstract][Full Text] [Related]
12. How small-molecule inhibitors of dengue-virus infection interfere with viral membrane fusion. Chao LH; Jang J; Johnson A; Nguyen A; Gray NS; Yang PL; Harrison SC Elife; 2018 Jul; 7():. PubMed ID: 29999491 [TBL] [Abstract][Full Text] [Related]
13. Structure of the dengue virus envelope protein after membrane fusion. Modis Y; Ogata S; Clements D; Harrison SC Nature; 2004 Jan; 427(6972):313-9. PubMed ID: 14737159 [TBL] [Abstract][Full Text] [Related]
14. Basic residues are critical to the activity of peptide inhibitors of human T cell leukemia virus type 1 entry. Lamb D; Mirsaliotis A; Kelly SM; Brighty DW J Biol Chem; 2009 Mar; 284(10):6575-84. PubMed ID: 19114713 [TBL] [Abstract][Full Text] [Related]
15. A peptide inhibitor derived from the conserved ectodomain region of DENV membrane (M) protein with activity against dengue virus infection. Panya A; Sawasdee N; Junking M; Srisawat C; Choowongkomon K; Yenchitsomanus PT Chem Biol Drug Des; 2015 Nov; 86(5):1093-104. PubMed ID: 25891143 [TBL] [Abstract][Full Text] [Related]
16. Crystal structure of dengue virus type 1 envelope protein in the postfusion conformation and its implications for membrane fusion. Nayak V; Dessau M; Kucera K; Anthony K; Ledizet M; Modis Y J Virol; 2009 May; 83(9):4338-44. PubMed ID: 19244332 [TBL] [Abstract][Full Text] [Related]
17. Highly specific inhibition of leukaemia virus membrane fusion by interaction of peptide antagonists with a conserved region of the coiled coil of envelope. Lamb D; Schüttelkopf AW; van Aalten DM; Brighty DW Retrovirology; 2008 Aug; 5():70. PubMed ID: 18680566 [TBL] [Abstract][Full Text] [Related]
18. Structural optimization and de novo design of dengue virus entry inhibitory peptides. Costin JM; Jenwitheesuk E; Lok SM; Hunsperger E; Conrads KA; Fontaine KA; Rees CR; Rossmann MG; Isern S; Samudrala R; Michael SF PLoS Negl Trop Dis; 2010 Jun; 4(6):e721. PubMed ID: 20582308 [TBL] [Abstract][Full Text] [Related]
19. Atomic-level functional model of dengue virus Envelope protein infectivity. Christian EA; Kahle KM; Mattia K; Puffer BA; Pfaff JM; Miller A; Paes C; Davidson E; Doranz BJ Proc Natl Acad Sci U S A; 2013 Nov; 110(46):18662-7. PubMed ID: 24158478 [TBL] [Abstract][Full Text] [Related]
20. An antiviral peptide targets a coiled-coil domain of the human T-cell leukemia virus envelope glycoprotein. Piñón JD; Kelly SM; Price NC; Flanagan JU; Brighty DW J Virol; 2003 Mar; 77(5):3281-90. PubMed ID: 12584351 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]